Cyto-histologic agreement in pathologic subtyping of non small cell lung carcinoma: Review of 602 fine needle aspirates with follow-up surgical specimens over a nine year period and analysis of factors underlying failure to subtype

Lung Cancer

Volumn 77, Issue 3, 2012, Pages 501-506

  Da Cunha Santos, Gilda ^a,b   Lai, Shui Wun ^a   Saieg, Mauro Ajaj ^a   Geddie, William R ^a,b   Pintilie, Melania ^c   Tsao, Ming Sound ^a,b   Boerner, Scott L ^a,b   Hwang, David ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Adenocarcinoma; Biopsy; Carcinoma; Cytology; Fine needle; Immunohistochemistry; Lung; Non small cell lung; Squamous cell

Indexed keywords

ANTIBODY; CYTOKERATIN 7; KERATIN; PROTEIN P63; THYROID TRANSCRIPTION FACTOR 1;

ARTICLE; ASPIRATION BIOPSY; CYTOLOGY; FOLLOW UP; HISTOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MORPHOLOGY; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; BIOPSY, FINE-NEEDLE; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; DELAYED DIAGNOSIS; DIAGNOSIS, DIFFERENTIAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG; LUNG NEOPLASMS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 84865179529     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2012.05.091     Document Type: Article

References (29)

1. Travis W.D., Brambilla E., Noguchi M., Nicholson A.G., Geisinger K.R., Yatabe Y., et al. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011, 6:244-285.
2. da Cunha Santos G., Shepherd F.A., Tsao M.S. EGFR mutations and lung cancer. Annu Rev Pathol 2011, 6:49-69.
3. Herbst R.S., O'Neill V.J., Fehrenbacher L., Belani C.P., Bonomi P.D., Hart L., et al. Phase II, study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. J Clin Oncol 2007, 25:4743-4750.
4. Sandler A. Bevacizumab in non small cell lung cancer. Clin Cancer Res 2007, 13:s4613-s4616.
5. Sandler A., Gray R., Perry M.C., Brahmer J., Schiller J.H., Dowlati A., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006, 355:2542-2550.
6. Gridelli C., Ardizzoni A., Douillard J.Y., Hanna N., Manegold C., Perrone F., et al. Recent issues in first-line treatment of advanced non-small-cell lung cancer: results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology. Lung Cancer 2010, 68:319-331.
7. Langer C.J., Besse B., Gualberto A., Brambilla E., Soria J.C. The evolving role of histology in the management of advanced non-small-cell lung cancer. J Clin Oncol 2010, 28:5311-5320.
8. Loo P.S., Thomas S.C., Nicolson M.C., Fyfe M.N., Kerr K.M. Subtyping of undifferentiated non-small cell carcinomas in bronchial biopsy specimens. J Thorac Oncol 2010, 5:442-447.
9. Ocque R., Tochigi N., Ohori N.P., Dacic S. Usefulness of immunohistochemical and histochemical studies in the classification of lung adenocarcinoma and squamous cell carcinoma in cytologic specimens. Am J Clin Pathol 2011, 136:81-87.
10. Cataluna J.J., Perpina M., Greses J.V., Calvo V., Padilla J.D., Paris F. Cell type accuracy of bronchial biopsy specimens in primary lung cancer. Chest 1996, 109:1199-1203.
11. Edwards S.L., Roberts C., McKean M.E., Cockburn J.S., Jeffrey R.R., Kerr K.M. Preoperative histological classification of primary lung cancer: accuracy of diagnosis and use of the non-small cell category. J Clin Pathol 2000, 53:537-540.
12. Thomas J.S., Lamb D., Ashcroft T., Corrin B., Edwards C.W., Gibbs A.R., et al. How reliable is the diagnosis of lung cancer using small biopsy specimens? Report of a UKCCCR Lung Cancer Working Party. Thorax 1993, 48:1135-1139.
13. Sigel C.S., Moreira A.L., Travis W.D., Zakowski M.F., Thornton R.H., Riely G.J., et al. Subtyping of non-small cell lung carcinoma: a comparison of small biopsy and cytology specimens. J Thorac Oncol 2011, 6:1849-1856.
14. Aikawa E., Kawahara A., Hattori S., Yamaguchi T., Abe H., Taira T., et al. Comparison of the expression levels of napsin A, thyroid transcription factor-1, and p63 in nonsmall cell lung cancer using cytocentrifuged bronchial brushings. Cancer Cytopathol 2011, 119:335-345.
15. Chhieng D.C., Cangiarella J.F., Zakowski M.F., Goswami S., Cohen J.M., Yee H.T. Use of thyroid transcription factor 1, PE-10, and cytokeratins 7 and 20 in discriminating between primary lung carcinomas and metastatic lesions in fine-needle aspiration biopsy specimens. Cancer 2001, 93:330-336.
16. Hecht J.L., Pinkus J.L., Weinstein L.J., Pinkus G.S. The value of thyroid transcription factor-1 in cytologic preparations as a marker for metastatic adenocarcinoma of lung origin. Am J Clin Pathol 2001, 116:483-488.
17. Jorda M., Gomez-Fernandez C., Garcia M., Mousavi F., Walker G., Mejias A., et al. p63 differentiates subtypes of nonsmall cell carcinomas of lung in cytologic samples: implications in treatment selection. Cancer 2009, 117:46-50.
18. Khayyata S., Yun S., Pasha T., Jian B., McGrath C., Yu G., et al. Value of p63 and CK5/6 in distinguishing squamous cell carcinoma from adenocarcinoma in lung fine-needle aspiration specimens. Diagn Cytopathol 2009, 37:178-183.
19. Wu M., Szporn A.H., Zhang D., Wasserman P., Gan L., Miller L., et al. Cytology applications of p63 and TTF-1 immunostaining in differential diagnosis of lung cancers. Diagn Cytopathol 2005, 33:223-227.
20. Lau S.K., Luthringer D.J., Eisen R.N. Thyroid transcription factor-1: a review. Appl Immunohistochem Mol Morphol 2002, 10:97-102.
21. Rekhtman N., Brandt S.M., Sigel C.S., Friedlander M.A., Riely G.J., Travis W.D., et al. Suitability of thoracic cytology for new therapeutic paradigms in non-small cell lung carcinoma: high accuracy of tumor subtyping and feasibility of EGFR and KRAS molecular testing. J Thorac Oncol 2011, 6:451-458.
22. Shtilbans V., Szporn A.H., Wu M., Burstein D.E. p63 immunostaining in destained bronchoscopic cytological specimens. Diagn Cytopathol 2005, 32:198-203.
23. Terry J., Leung S., Laskin J., Leslie K.O., Gown A.M., Ionescu D.N. Optimal immunohistochemical markers for distinguishing lung adenocarcinomas from squamous cell carcinomas in small tumor samples. Am J Surg Pathol 2010, 34:1805-1811.
24. Cohen M.H., Johnson J.R., Chen Y.F., Sridhara R., Pazdur R. FDA drug approval summary: erlotinib (Tarceva) tablets. Oncologist 2005, 10:461-466.
25. Shepherd F.A., Rodrigues Pereira J., Ciuleanu T., Tan E.H., Hirsh V., Thongprasert S., et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005, 353:123-132.
26. Nizzoli R., Tiseo M., Gelsomino F., Bartolotti M., Majori M., Ferrari L., et al. Accuracy of fine needle aspiration cytology in the pathological typing of non-small cell lung cancer. J Thorac Oncol 2011, 6:489-493.
27. Righi L., Graziano P., Fornari A., Rossi G., Barbareschi M., Cavazza A., et al. Immunohistochemical subtyping of nonsmall cell lung cancer not otherwise specified in fine-needle aspiration cytology: a retrospective study of 103 cases with surgical correlation. Cancer 2011, 117:3416-3423.
28. Coghlin C.L., Smith L.J., Bakar S., Stewart K.N., Devereux G.S., Nicolson M.C., et al. Quantitative analysis of tumor in bronchial biopsy specimens. J Thorac Oncol 2010, 5:448-452.
29. Ou S.H., Zell J.A. Carcinoma NOS is a common histologic diagnosis and is increasing in proportion among non-small cell lung cancer histologies. J Thorac Oncol 2009, 4:1202-1211.